Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
|Articles|July 10, 2020
Bringing 2 to 4 Antibiotics for AMR to Market by 2030
Author(s)John Parkinson
Biopharmaceutical companies create nearly $1 billion fund to aid much needed pipeline for antimicrobial resistance.
Advertisement
Over 20 biopharmaceutical companies have joined together to launch an initiative to develop 2-4 antibiotics in 10 years for antimicrobial resistance (AMR).
To aid with the research and development, the companies announced the launch of the
The AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (
The AMR Action Fund expects to invest its current funding as well as future support from partners to address the funding gap for the financing of antibiotic development.
“With the AMR Action Fund, the pharmaceutical industry is investing nearly $1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” Chairman and CEO of Eli Lilly and Company and President of IFPMA David Ricks said.
“The AMR Action Fund is one of the largest and most ambitious collaborative initiatives ever undertaken by the pharmaceutical industry to respond to a global public health threat,” Director General of the IFPMA Thomas Cueni stated.
The fund was developed by the IFPMA, the Biopharmaceutical CEOs Roundtable, and biopharmaceutical companies and foundations, in collaboration with the World Health Organization, The European Investment Bank, and the Wellcome Trust.
The fund organizers have discussed how they will invest in AMR research, and those initiatives include:
- Invest in smaller biotech companies focused on developing innovative antibacterial treatments that address the highest priority public health needs, make a significant difference in clinical practice, and save lives.
- Provide technical support to portfolio companies, giving them access to the deep expertise and resources of large biopharmaceutical companies, to strengthen antibiotic development, and support access and appropriate use of antibiotics.
- Bring together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilateral organizations, and help encourage governments to create market conditions that enable sustainable investment in the antibiotic pipeline.
“Unlike COVID-19, AMR is a predictable and preventable crisis. We must act together to rebuild the pipeline and ensure that the most promising and innovative antibiotics make it from the lab to patients,” Cueni stated.
Biopharmaceutical companies and foundations supporting the fund include: Almirall, Amgen, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, LEO Pharma, Lundbeck, Menarini, Merck, MSD, Novartis, Novo Nordisk, Novo Nordisk Foundation, Pfizer, Roche, Shionogi, Takeda, Teva, and UCB.
The fund is expected to be operational during the fourth quarter of 2020.
Advertisement
Related to this article
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Adding bismuth to amoxicillin-vonoprazan increased efficacy of the combination for H pylori, and exceeded that of clarithromycin-based triple therapy without contributing to clarithromycin resistance.
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Advertisement
Advertisement
Trending on Contagion Live
1
How The Food Safety Surveillance Infrastructure Works in the US
2
Evaluating Ebola Vaccine Against Current Bundibugyo Species
3
Implanted Antibiotic Reduced Systemic Regimen for Orthopedic Infection
4
Ebola and the Ongoing Tale of US Failures
5